{"id":619238,"date":"2022-09-30T14:06:01","date_gmt":"2022-09-30T14:06:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=619238"},"modified":"2022-09-30T14:06:01","modified_gmt":"2022-09-30T14:06:01","slug":"graves-disease-market-to-register-growth-at-an-extraordinary-cagr-by-2032-delveinsight-major-companies-novartis-and-several-others","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/graves-disease-market-to-register-growth-at-an-extraordinary-cagr-by-2032-delveinsight-major-companies-novartis-and-several-others_619238.html","title":{"rendered":"Graves\u2019 Disease Market to Register Growth at an Extraordinary CAGR by 2032, DelveInsight | Major Companies &#8211; Novartis, and Several Others"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1664523558.png\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Graves&rsquo; Disease Market to Register Growth at an Extraordinary CAGR by 2032, DelveInsight | Major Companies - Novartis, and Several Others\" src=\"https:\/\/www.abnewswire.com\/uploads\/1664523558.png\" alt=\"Graves&rsquo; Disease Market to Register Growth at an Extraordinary CAGR by 2032, DelveInsight | Major Companies - Novartis, and Several Others\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<p style=\"text-align: justify;\">The Graves &rsquo; disease Market is expected to show positive growth in the forecast period (2022&ndash;2032) due to the development of well-designed, randomized, controlled non-crossover trials with potential benefits. Moreover, the shortfall of approved therapy might provide suitable space for emerging therapies.<\/p>\n<p style=\"text-align: justify;\">DelveInsight&#8217;s <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/graves-disease-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Graves&rsquo; Disease Market Insights<\/a> report includes a comprehensive understanding of current treatment practices, Graves&rsquo; Disease emerging drugs, Graves&rsquo; Disease market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU5 (the United Kingdom, Italy, Spain, France, and Germany), Japan].<\/p>\n<p style=\"text-align: justify;\"><strong>Key takeaways from the Graves&rsquo; Disease Market Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>According to Graves&rsquo; disease and thyroid foundation, Graves&rsquo; disease, also known as toxic diffuse goiter, is the most common cause of hyperthyroidism &ndash; a disorder that occurs when the thyroid gland makes more thyroid hormone than the body needs.<\/li>\n<li>According to the National Institute of Diabetes and Digestive and Kidney Diseases (n.d.), the disease affects about 1 in 200 people in the United States and is the most common cause of hyperthyroidism.<\/li>\n<li>According to an article by Wemeau et al. (2018), of 1,572 hyperthyroid patients living in France, 73.3% had Graves&rsquo; disease (either primary or recurrence), of whom 85% were female, with a mean age of 43 years (primary and onset) to 44 years (recurrence).<\/li>\n<li>The National Institute of Diabetes and Digestive and Kidney Diseases (n.d.), estimates that 30 percent of people who develop Graves&rsquo; disease will get a mild case of Graves&rsquo; ophthalmopathy. Up to 5 percent will get severe Graves&rsquo; ophthalmopathy.<\/li>\n<li>Leading Graves&rsquo; Disease Companies includes Novartis, and Many Others<\/li>\n<li>The promising Graves&rsquo; Disease Therapies in the pipeline includes Secukinumab, and Many Others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Know which therapies are expected to grab major Graves&rsquo; Disease Market Share @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/graves-disease-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Graves&rsquo; Disease Market Research Report<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Graves&rsquo; disease Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Graves&#8217; disease is an autoimmune disorder that causes hyperthyroidism or overactive thyroid. With this disease, the immune system attacks the thyroid and causes it to make more thyroid hormone than the body needs. The thyroid is a small, butterfly-shaped gland in the front of your neck. Thyroid hormones control how the body uses energy, so they affect nearly every organ in your body&mdash;even the way heartbeats. If left untreated, hyperthyroidism can cause serious problems with the heart, bones, muscles, menstrual cycle, and fertility. During pregnancy, untreated hyperthyroidism can lead to health problems for the mother and baby. Graves&rsquo; disease also can affect the eyes and skin.<\/p>\n<p style=\"text-align: justify;\">Graves&#8217; disease is an autoimmune disorder that causes hyperthyroidism or overactive thyroid. With this disease, the immune system attacks the thyroid and causes it to make more thyroid hormone than the body needs. The thyroid is a small, butterfly-shaped gland in the front of your neck. Thyroid hormones control how the body uses energy, so they affect nearly every organ in your body&mdash;even the way heartbeats. If left untreated, hyperthyroidism can cause serious problems with the heart, bones, muscles, menstrual cycle, and fertility. During pregnancy, untreated hyperthyroidism can lead to health problems for the mother and baby. Graves&rsquo; disease also can affect the eyes and skin.<\/p>\n<p style=\"text-align: justify;\"><strong>Graves&rsquo; disease Epidemiology Segmentation in the 7MM<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Total Graves&rsquo; disease incident population<\/li>\n<li>Graves&rsquo; disease Diagnosed incident population,<\/li>\n<li>Graves&rsquo; disease Age-specific incident population<\/li>\n<li>Graves&rsquo; disease Gender-specific incident population and by Clinical Manifestations<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>For further information of this report to understand which factors are driving Graves&rsquo; disease epidemiology trends @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/graves-disease-epidemiology-forecast?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Graves&rsquo; disease Epidemiological Insights<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Graves&rsquo; Disease Treatment Market<\/strong><\/p>\n<p style=\"text-align: justify;\">There are three treatment options for the individuals affected with Graves&rsquo; disease viz; medicine, radioiodine therapy and thyroid surgery. Radioiodine therapy is the most common treatment for Graves&rsquo; disease in the United States, but doctors are beginning to use medicine more often than in the past. Age, Pregnancy, presence of other medical conditions determines the right treatment for the patients.<\/p>\n<p style=\"text-align: justify;\"><strong>Graves&rsquo; Disease Market Insights<\/strong><\/p>\n<p style=\"text-align: justify;\">The conventional therapeutic options for Graves&rsquo; disease have not improved over the past 70 years, despite substantial unmet clinical need and a significant lack of efficacy for many patients. The demand for innovative therapeutic options has led to the emergence of novel approaches in the treatment of Graves&rsquo; hyperthyroidism, including biologic, small molecule, and peptide immunomodulation, several of which have translational potential into clinical practice in the near future. Targeting the direct cause of hyperthyroidism in Graves&rsquo; disease using TSHR-specific modalities, has a clear advantage in providing a targeted approach while avoiding disruption of a functioning immune system.<\/p>\n<p style=\"text-align: justify;\"><strong>Graves&rsquo; Disease Pipeline Companies and Therapies<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Novartis: Secukinumab<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Learn more about the Graves&rsquo; Disease therapies in clinical trials @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/graves-disease-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Drugs for Graves&rsquo; Disease Treatment<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Graves&rsquo; Disease Market Size<\/strong><\/p>\n<p style=\"text-align: justify;\">The Graves&rsquo; Disease market size is anticipated to increase during the study period owing to the increasing incident population and rising awareness of the Graves&rsquo; Disease Market in the 7MM. The expected launch of emerging therapies and the research and development activities of pharmaceutical companies will also fuel the market growth during the forecast period.<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the Graves&rsquo; Disease Market Forecast Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Coverage- 7MM<\/li>\n<li>Study Period- 2019-2032<\/li>\n<li>Forecast Period- 2022-2032<\/li>\n<li>Graves&rsquo; Disease Companies includes Novartis, and Many Others<\/li>\n<li>Graves&rsquo; Disease Therapies in the pipeline includes Secukinumab, and Many Others<\/li>\n<li>Graves&rsquo; Disease Therapeutic Assessment- Current marketed and emerging therapies<\/li>\n<li>Graves&rsquo; Disease Market Dynamics- Graves&rsquo; Disease Market Drivers and Barriers<\/li>\n<li>Competitive Intelligence Analysis- SWOT analysis, PESTLE analysis, Porter&#8217;s five forces, BCG Matrix, Market entry strategies<\/li>\n<li>Unmet Needs, KOL&#8217;s views, Analyst&#8217;s views, Graves&rsquo; Disease Market Access and Reimbursement<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Table of Content<\/strong><\/p>\n<ol style=\"text-align: justify;\" start=\"1\">\n<li>Key Insights<\/li>\n<li>Graves&rsquo; Disease Executive Summary<\/li>\n<li>Graves&rsquo; Disease Competitive Intelligence Analysis<\/li>\n<li>Graves&rsquo; Disease Market Overview at a Glance<\/li>\n<li>Disease Background and Overview<\/li>\n<li>Patient Journey<\/li>\n<li>Graves&rsquo; Disease Epidemiology and Patient Population<\/li>\n<li>Treatment Algorithm, Current Treatment, and Medical Practices<\/li>\n<li>Unmet Needs<\/li>\n<li>Key Endpoints of Graves&rsquo; Disease Market Treatment<\/li>\n<li>Marketed Products<\/li>\n<li>Emerging Therapies<\/li>\n<li>Seven Major Market Analysis<\/li>\n<li>Attribute analysis<\/li>\n<li>7MM: Graves&rsquo; Disease Market Outlook<\/li>\n<li>Access and Reimbursement Overview<\/li>\n<li>KOL Views<\/li>\n<li>Graves&rsquo; Disease Market Drivers<\/li>\n<li>Graves&rsquo; Disease Market Barriers<\/li>\n<li>Appendix<\/li>\n<li>DelveInsight Capabilities<\/li>\n<li>Disclaimer<\/li>\n<li>About DelveInsight<\/li>\n<\/ol>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Discover more about Graves&rsquo; Disease Medications in development @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/graves-disease-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Graves&rsquo; Disease Clinical Trials<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About Us<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&amp;D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers &amp; Acquisitions.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_72253.html\" rel=\"nofollow\">DelveInsight<\/a><br \/><strong>Contact Person:<\/strong> Yash<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=graves-disease-market-to-register-growth-at-an-extraordinary-cagr-by-2032-delveinsight-major-companies-novartis-and-several-others\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +919650213330<br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=graves-disease-market-to-register-growth-at-an-extraordinary-cagr-by-2032-delveinsight-major-companies-novartis-and-several-others\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The Graves &rsquo; disease Market is expected to show positive growth in the forecast period (2022&ndash;2032) due to the development of well-designed, randomized, controlled non-crossover trials with potential benefits. Moreover, the shortfall of approved therapy might provide suitable space for &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/graves-disease-market-to-register-growth-at-an-extraordinary-cagr-by-2032-delveinsight-major-companies-novartis-and-several-others_619238.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[405,406,403,404],"tags":[],"class_list":["post-619238","post","type-post","status-publish","format-standard","hentry","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/619238","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=619238"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/619238\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=619238"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=619238"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=619238"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}